Table 3.

Cox proportional univariate and multivariate analysis to identify factors independently associated with clinically significant MR regression.

POTENTIAL PREDICTORS OF MITRAL VALVE REGRESSION	UNIVARIATE ANALYSIS		MULTIVARIATE ANALYSIS
	HR (95%CI)	p*	AHR (95%CI)	p
Age at presentation	0.93 (0.83–1.04)	0.218
Female gender	1.06 (0.59–1.91)	0.842
Domicile in capital city	0.90 (0.47–1.72)	0.747
ESR level	1.01 (1.00–1.02)	0.007	1.01 (1.01 – 1.03)	0.01
CRP level	1.00 (1.00–1.01)	0.798
Presented with heart failure	1.35 (0.73–2.50)	0.332
Severe carditis at presentation	5.83 (1.80–18.91)	0.003	4.14 (1.02–16.86)	0.05
Administration of glucocorticoids	0.99 (0.93–1.06)	0.759
Duration of prednisolone treatment	0.99 (0.95–1.03)	0.590
Duration of ASA treatment	1.00 (0.99–1.01)	0.741
Duration of bed rest	1.00 (0.99–1.01)	0.741
Good compliance with ATB prophylaxis	1.29 (0.54–3.04)	0.566
Presence with MR alone	0.56 (0.26–1.20)	0.136
Z-score LVEDD at presentation	1.39 (1.15 – 1.69)	0.001	1.12 (0.87 – 1.46)	0.381
Z-score LVESD at presentation	1.46 (1.16 – 1.83)	0.001
LVEF	1.00 (0.95–1.06)	0.919
Z-score LVEDD at last follow up	0.94 (0.80 – 1.10)	0.426
Z-score LVESD at last follow up	0.97 (0.93 – 1.14)	0.727
History of recurrent ARF	0.89 (0.38–2.11)	0.793

A p-value < 0.05 is considered statistically significant.

*Factors with a p-value < 0.20 from univariate logistic regression analysis were included in the multivariate analysis.

Abbreviations: aHR, adjusted hazard ratio; AR, aortic valve regurgitation; ASA, acetylsalicylic acid or aspirin; ATB, antibiotic drugs; CI, confidence interval; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; HR, hazard ratio; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic diameter; MR, mitral valve regurgitation.